Cellectar Q3 cash $34.3M; raised $19.4M with potential $73.3M; positive WM data supports NDA

Cellectar Biosciences, Inc.

2024-Q3 EPS reported -$1.39

Cash $34.3M at Sept 30, 2024, up from $9.6M at Dec 31, 2023; raised $19.4M from warrant exercises with potential for additional $73.3M.
Q3 R&D expenses $5.5M (down from $7.0M YoY) due to end of WM pivotal enrollment; G&A $7.8M (up from $2.4M YoY) for commercialization prep.
Positive Phase 2 CLOVER-WaM results for iopofosine I 131 in WM; planning near-term NDA submission for accelerated approval.
Data selected for oral presentation at ASH meeting on Dec 9, 2024.
Entered supply agreements (SpectronRx, Northstar) and collaboration with City of Hope for mycosis fungoides.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.